These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1956867)

  • 1. The influence of age on the pharmacokinetics of verapamil.
    Ahmed JH; Meredith PA; Elliott HL
    Pharmacol Res; 1991 Oct; 24(3):227-33. PubMed ID: 1956867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.
    Gupta S; Modi NB; Sathyan G; Ho Pl PL; Aarons L
    Biopharm Drug Dispos; 2002 Jan; 23(1):17-31. PubMed ID: 11891670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
    Dadashzadeh S; Javadian B; Sadeghian S
    Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients.
    Hanyok JJ; Chow MS; Kluger J; Izard MW
    J Clin Pharmacol; 1988 Sep; 28(9):831-6. PubMed ID: 3230150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers.
    Schwartz JB; Capili H; Wainer IW
    Clin Pharmacol Ther; 1994 Oct; 56(4):368-76. PubMed ID: 7955798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics.
    Schwartz JB; Capili H; Daugherty J
    Clin Pharmacol Ther; 1994 May; 55(5):509-17. PubMed ID: 8181195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging alters verapamil elimination and dynamics: single dose and steady-state responses.
    Schwartz JB
    J Pharmacol Exp Ther; 1990 Oct; 255(1):364-73. PubMed ID: 2213568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.
    Carosella L; Menichelli P; Alimenti M; Zuccala G; Gemma A; Cocchi A; Carbonin PU
    Cardiovasc Drugs Ther; 1989 Jun; 3(3):417-25. PubMed ID: 2487538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil.
    Schwartz JB; Troconiz IF; Verotta D; Liu S; Capili H
    J Pharmacol Exp Ther; 1993 May; 265(2):690-8. PubMed ID: 8496816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of age and gender on the stereoselective pharmacokinetics of verapamil.
    Sasaki M; Tateishi T; Ebihara A
    Clin Pharmacol Ther; 1993 Sep; 54(3):278-85. PubMed ID: 8375122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.
    Ho PC; Ghose K; Saville D; Wanwimolruk S
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):693-8. PubMed ID: 11214778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Atkinson L; Tu T; Longstreth JA
    Br J Clin Pharmacol; 1995 Oct; 40(4):325-31. PubMed ID: 8554934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of verapamil in patients with hypertension.
    Anderson P; Bondesson U; de Faire U
    Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity.
    Bhatti MM; Lewanczuk RZ; Pasutto FM; Foster RT
    J Clin Pharmacol; 1995 Nov; 35(11):1076-82. PubMed ID: 8626881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of racemic verapamil in patients with impaired renal function.
    Zachariah PK; Moyer TP; Theobald HM; Frantz RP; Kurtz SB; McCarthy JT; Smith RL
    J Clin Pharmacol; 1991 Jan; 31(1):45-53. PubMed ID: 2045528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Yih BM; Atkinson L; Longstreth J
    J Clin Pharmacol; 1995 Nov; 35(11):1083-93. PubMed ID: 8626882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.
    Eichelbaum M; Somogyi A
    Eur J Clin Pharmacol; 1984; 26(1):47-53. PubMed ID: 6714292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits.
    Siegner SW; Giovanoni RL; Erickson KA; Netland PA
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):159-68. PubMed ID: 9572542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verapamil pharmacodynamics and disposition in obese hypertensive patients.
    Abernethy DR; Schwartz JB
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):209-15. PubMed ID: 2452316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.